Novo Nordisk: Underestimated the Market Potential for GLP-1 Pills! By 2030, Oral Medications Could Dominate Over a Third of the Market!
Reading Time: 2 minutes
In the TraderFox model portfolio, we invested 44.99 Euros in Novo Nordisk on January 5, 2026. We followed this strategy because the stock broke out of the Pivotal Base on that day. The Pivotal News Point was created on December 23, 2025, with the FDA approval for the Wegovy pill. Wegovy Pill Goes on Sale The U.S. market launch of the Wegovy pill in January marks a strategic milestone. With a presence in over 70,000 drugstores and listing on Amazon Pharmacy, comprehensive availability is ensured from day one. Analysts conservatively estimate the...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
